Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25055
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBhurani, Mansi-
dc.contributor.authorAdmojo, Lorenz-
dc.contributor.authorVan Der Weyden, Carrie-
dc.contributor.authorTwigger, Robert-
dc.contributor.authorBazargan, Ali-
dc.contributor.authorQuach, Hang-
dc.contributor.authorZimet, Allan-
dc.contributor.authorCoyle, Luke-
dc.contributor.authorLindsay, Julian-
dc.contributor.authorRadeski, Dejan-
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorKennedy, Glen-
dc.contributor.authorIrving, Ian-
dc.contributor.authorGutta, Naadir-
dc.contributor.authorTrotman, Judith-
dc.contributor.authorYeung, James-
dc.contributor.authorDunlop, Lindsay-
dc.contributor.authorHua, Minh-
dc.contributor.authorGiri, Pratyush-
dc.contributor.authorYuen, Sam-
dc.contributor.authorPanicker, Shyam-
dc.contributor.authorMoreton, Susan-
dc.contributor.authorKhoo, Liane-
dc.contributor.authorScott, Ashleigh-
dc.contributor.authorKipp, David-
dc.contributor.authorMcQuillan, Andrew-
dc.contributor.authorMcCormack, Chris-
dc.contributor.authorDickinson, Michael-
dc.contributor.authorPrince, Henry Miles-
dc.date2020-10-07-
dc.date.accessioned2020-10-15T03:16:44Z-
dc.date.available2020-10-15T03:16:44Z-
dc.date.issued2021-02-
dc.identifier.citationLeukemia & Lymphoma 2021; 62(2): 330-336en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/25055-
dc.description.abstractWe present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan-Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (nā€‰=ā€‰11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study - the second largest real-world cohort reported to date - underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile.en
dc.language.isoeng-
dc.subjectPralatrexateen
dc.subjectT-cell lymphomaen
dc.subjectcutaneous T-cell lymphomaen
dc.subjectmucositisen
dc.subjectperipheral T-cell lymphomaen
dc.titlePralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.en
dc.typeJournal Articleen
dc.identifier.journaltitleLeukemia & Lymphomaen
dc.identifier.affiliationRoyal Adelaide Hospital, Adelaide, SA, Australiaen
dc.identifier.affiliationSouthern Highland Private Hospital, Liverpool, NSW, Australiaen
dc.identifier.affiliationRoyal Prince Alfred Hospital, Sydney, NSW, Australiaen
dc.identifier.affiliationConcord Hospital, Sydney, NSW, Australiaen
dc.identifier.affiliationIcon Cancer Care, Brisbane, QLD, Australiaen
dc.identifier.affiliationMater Cancer Care Centre, Brisbane, QLD, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationHollywood Medical Centre, Nedlands, WA, Australiaen
dc.identifier.affiliationBarwon Health Cancer Services, Geelong, VIC, Australiaen
dc.identifier.affiliationHills Specialist Group, Bella Vista, NSW, Australiaen
dc.identifier.affiliationCalvary Mater, Newcastle, NSW, Australiaen
dc.identifier.affiliationSt Vincent's Health, Melbourne, VIC, Australiaen
dc.identifier.affiliationRoyal Brisbane and Women's Hospital, Herston, QLD, Australiaen
dc.identifier.affiliationSir Peter MacCallum Department of Surgical Oncology, Parkville, VIC, Australiaen
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationSir Charles Gairdner Hospital, Nedlands, WA, Australiaen
dc.identifier.affiliationRoyal North Shore Hospital, Sydney, NSW, Australiaen
dc.identifier.affiliationFaculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, VIC, Australiaen
dc.identifier.affiliationDivision of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australiaen
dc.identifier.affiliationDubbo Base Hospital, Dubbo, NSW, Australiaen
dc.identifier.affiliationEpworth Healthcare, Melbourne, VIC, Australiaen
dc.identifier.doi10.1080/10428194.2020.1827241en
dc.type.contentTexten
dc.identifier.orcid0000-0001-6566-6215en
dc.identifier.orcid0000-0002-4796-3352en
dc.identifier.pubmedid33026266-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Jun 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.